Frontier Pharma: Breast Cancer-First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Canc


Free Press Release DB | Press Release Date : May 20, 2019  Download


Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer co


In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5-and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

Early buyers will receive 10% customization on reports.

Request Sample Copy at https://www.premiummarketinsights.com/sample/GBI00004583

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

-Unmet need is extremely high in late-stage breast cancer.
-What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer-
-What is the current treatment algorithm-
-How effective are current therapies for these indications, and how does this impact prognosis-
-The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation.
-Which molecule types and molecular targets are most prominent across the breast cancer pipeline-
-What are the relationships between established and up-coming molecular targets in breast cancer-
-Which first-in-class targets are most promising-
-How does first-in-class target diversity differ by stage of development and molecular target class-
-The deals landscape is active and dominated by very high and very low deal values.
-Which indications attract the highest deal values-
-How has deal activity fluctuated over the past decade-
-Which first-in-class pipeline products have no prior involvement in licensing or co-development deals-

Request for Discount at https://www.premiummarketinsights.com/discount/GBI00004583

Reasons to buy

-Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
-Identify leading products and key unmet needs within the market.
-Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
-Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
-Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

Table of Contents:

1 Table of Contents 2

2 Executive Summary 6

3 The Case for Innovation 7

4 Clinical and Commercial Landscape 11

5 Assessment of Pipeline Product Innovation 29

6 Signaling Network, Disease Causation and Innovation Alignment 62

7 First-in-Class Target Evaluation 70

8 Strategic Consolidations 83

9 Appendix 105

For more information about this report: https://www.premiummarketinsights.com/reports-gbi/frontier-pharma-breast-cancer-first-in-class-innovation-underlies-immunotherapeutic-potential-and-pipeline-diversification-for-late-stage-breast-cancer

Contact Info:
Name: Sameer Joshi
Email: sales@premiummarketinsights.com
Organization: Premium Market Insights
Phone: +1-646-491-9876

About Premium Market Insights:

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.




Contact Person & Company

Name

:

Rahul Desai

Company

:

Premium Market Insights

Contact Numbers

Telephone No.

:

Fax No.

:

Handphone No.

:

Website

Website 1

:

Website 2

:

Youtube

:

PR Tags

:

Frontier Pharma Breast Cancer-first-in-class Innovation Underlies Immunotherapeutic Potential And Pipeline Diversification For Late-stage Breast Cancer,

Address


Contact The Author



Contact Rahul Desai






More Press Release From Author



Apoptosis Assays Market Top Segments, Key Players Revenue, Growth Rate and Forecasts Till 2027


Free Press Release DB :

Apoptosis Assays Market to 2027 - Global Analysis and Forecasts By Product (Assay Kits, Reagents, Microplates and Instruments), Application (Clinical & Diagnostic Applications, Drug Discovery & Development, Stem Cell Research and Basic Research), End --> Read This Press Release !



By : Rahul , Desai ( Jun 18, 2019 )
Category : Business Press Release | Country : India Press Release




Cell Culture Market Outlook, Research, Growth Strategies and Comprehensive Forecast to 2027| Thermo Fisher Scientific, General Electric Company, Corni


Free Press Release DB :

Cell Culture Market to 2027 - Global Analysis and Forecasts By Product (Equipment and Consumables); Application (Biopharmaceutical Therapeutics, Stem Cell Technology, Cancer Research, Drug Screening and Development, Tissue Engineering and Regenerativ --> Read This Press Release !



By : Rahul , Desai ( Jun 18, 2019 )
Category : Business Press Release | Country : India Press Release




Immunochemistry Instruments and Reagents Market Top Segments, Key Players Revenue, Growth Rate and Forecasts Till 2027


Free Press Release DB :

Immunochemistry Instruments and Reagents Market to 2027 - Global Analysis and Forecasts By Product (Instruments and Consumables), Application (Cardiology, Endocrinology, Oncology, Therapeutic Drug Development & Monitoring, Infectious Disease Testing, --> Read This Press Release !



By : Rahul , Desai ( Jun 18, 2019 )
Category : Business Press Release | Country : India Press Release





Read More Articles From Rahul Desai



Disclaimer

The author of the press releases are solely responsible for the content of their press releases. Freepressreleasedb.com can't be held liable for the content posted by author. Please check the accuracy of the press release before using the press release. If necessary please contact the author. Thank you.




Report Abuse